Education
About Us
Working with TipRanks
Follow Us
Fusion Antibodies Plc (GB:FAB)
LSE:FAB
RESEARCH TOOLSreports
Total Valuation
Fusion Antibodies Plc has a market cap or net worth of £7.56M. The enterprise value is 9.90M.
Market Cap£7.56M
Enterprise Value9.90M
Share Statistics
Fusion Antibodies Plc has 113,656,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,656,250
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Fusion Antibodies Plc’s return on equity (ROE) is -1.24 and return on invested capital (ROIC) is -119.88%.
Return on Equity (ROE)-1.24
Return on Assets (ROA)-0.92
Return on Invested Capital (ROIC)-119.88%
Return on Capital Employed (ROCE)-1.25
Revenue Per Employee42.07K
Profits Per Employee-82.44K
Employee Count27
Asset Turnover0.47
Inventory Turnover3.05
Valuation Ratios
The current PE Ratio of Fusion Antibodies Plc is -0.96. Fusion Antibodies Plc’s PEG ratio is -0.03.
PE Ratio-0.96
PS Ratio0.00
PB Ratio8.92
Price to Fair Value1.19
Price to FCF-5.36
Price to Operating Cash Flow-5.71
PEG Ratio-0.03
Income Statement
In the last 12 months, Fusion Antibodies Plc had revenue of 1.14M and earned -2.23M in profits. Earnings per share was -0.04.
Revenue1.14M
Gross Profit-265.00K
Operating Income-2.29M
Pretax Income-2.29M
Net Income-2.23M
EBITDA-2.06M
Earnings Per Share (EPS)-0.04
Cash Flow
In the last 12 months, operating cash flow was -1.17M and capital expenditures -2.00K, giving a free cash flow of -1.17M billion.
Operating Cash Flow-1.17M
Free Cash Flow-1.17M
Free Cash Flow per Share-0.01
Dividends & Yields
Fusion Antibodies Plc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.26
52-Week Price Change92.75%
50-Day Moving Average6.49
200-Day Moving Average6.07
Relative Strength Index (RSI)53.14
Average Volume (3m)610.27K
Important Dates
Fusion Antibodies Plc upcoming earnings date is Nov 19, 2024, TBA Not Confirmed.
Last Earnings DateSep 5, 2024
Next Earnings DateNov 19, 2024
Ex-Dividend Date―
Financial Position
Fusion Antibodies Plc as a current ratio of 3.87, with Debt / Equity ratio of 6.68%
Current Ratio3.87
Quick Ratio3.09
Debt to Market Cap0.00
Net Debt to EBITDA0.56
Interest Coverage Ratio-457.60
Taxes
In the past 12 months, Fusion Antibodies Plc has paid -63.00K in taxes.
Income Tax-63.00K
Effective Tax Rate0.03
Enterprise Valuation
Fusion Antibodies Plc EV to EBITDA ratio is -0.48, with an EV/FCF ratio of -0.56.
EV to Sales0.87
EV to EBITDA-0.48
EV to Free Cash Flow-0.56
EV to Operating Cash Flow-0.56
Balance Sheet
Fusion Antibodies Plc has £439.00K in cash and marketable securities with £32.00K in debt, giving a net cash position of -£407.00K billion.
Cash & Marketable Securities£439.00K
Total Debt£32.00K
Net Cash-£407.00K
Net Cash Per Share>-£0.01
Tangible Book Value Per Share£0.03
Margins
Gross margin is 6.96%, with operating margin of -201.41%, and net profit margin of -195.95%.
Gross Margin6.96%
Operating Margin-201.41%
Pretax Margin-201.50%
Net Profit Margin-195.95%
EBITDA Margin-181.78%
EBIT Margin-201.06%
Analyst Forecast
The average price target for Fusion Antibodies Plc is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast14.12%
EPS Growth Forecast78.16%